Autres langues Axsome Therapeutics, Inc.

Actions

AXSM

US05464T1043

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 04/08/2026			Après clôture 00:14:59
212,17 ^USD	+0,54%		218,25	+2,87%

31/07	AXSOME THERAPEUTICS, INC. : Opinion positive de Mizuho Securities	ZM
21/07	AXSOME THERAPEUTICS, INC. : BMO Capital optimiste sur le dossier	ZM

Autres langues

15/07	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
15/07	Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application
15/07	Axsome's New Drug Application for Narcolepsy Treatment Accepted by FDA
15/07	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
14/07	Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
07/07	Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial Of Solriamfetol In Children With Attention Deficit Hyperactivity Disorder
07/07	Axsome Therapeutics Doses First Patient in Trial of Potential ADHD Drug
07/07	Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
07/07	Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
29/06	Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Index
29/06	Axsome Therapeutics, Inc.(NasdaqGM:AXSM) added to Russell Midcap Growth Benchmark
29/06	Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Growth Benchmark
29/06	Axsome Therapeutics, Inc.(NasdaqGM:AXSM) added to Russell 1000 Growth Benchmark
29/06	Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Dynamic Index
29/06	Axsome Therapeutics, Inc.(NasdaqGM:AXSM) added to Russell 1000 Dynamic Index
29/06	Axsome Therapeutics, Inc.(NasdaqGM:AXSM) added to Russell Midcap Index
29/06	Axsome Therapeutics, Inc.(NasdaqGM:AXSM) added to Russell 1000 Index
26/06	Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial Of Solriamfetol In Adolescents With Attention Deficit Hyperactivity Disorder
26/06	Axsome Therapeutics Says First Patient Dosed in Phase 3 Solriamfetol ADHD Study
26/06	Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
22/06	Definium's LSD-based depression pill delivers strong late-stage results, shares surge
18/06	Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
15/06	Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
05/06	Axsome Therapeutics Presents New SYMBRAVO Data at the Americal Headache Society 68th Annual Scientific Meeting
04/06	Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting